drugset
drugset / Trial / NCT07082829

A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age

NCT07082829 ↗

Phase 1 Recruiting 208 enrolled Centessa Pharmaceuticals (UK) Limited
RandomizedParallel-groupDouble-blindTreatment

Summary

Characterize the safety, tolerability and pharmacokinetics of ORX142 following single and multiple doses.

Timeline

Start
2025-06-30
Primary completion
2026-06-15
Completion
2026-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject ORX142 Unknown — —

Indications

hypersomnia